In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 442 for your search:
Drug:  irinotecan hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase IV
Type: Diagnostic, Treatment
Status: Completed
Age: 18 to 85
Sponsor: Other
Protocol IDs: COLOGEN, NCT00138060
2.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000574159, CHUL-BIO-COLON, INCA-RECF0356, RECF0356, NCT00559676
3.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CPT_08_001, NCT01271582
4.

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000430100, FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
5.

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 02-0484-C, NCT00160875
6.

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 01023010 / TOP-003, NCT00284258
7.

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Other
Protocol IDs: JACCRO GC-05, NCT00639327
8.

Phase: Phase III, Phase II
Type: Diagnostic, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UKM-MRC-FOCUS3-CR12, FOCUS 3 - CR12, EUDRACT-2008-008323-15, ISRCTN83171665, EU-20960, NCT00975897
9.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-95051, P-UPJOHN-MSKCC-95051, NCI-V96-0913
10.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000066151, FRE-GERCOR-C97-3/CPTF308, FRE-C97-3/CPTF301, FRE-C97-3/CPTF308, RP-FRE-C97-3/CPTF308, EU-97044, NCT00003260
11.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CLB-89803, CAN-NCIC-CO15, E-89803, NCCTG-C89803, SWOG-C89803, NCT00003835, C89803, CO15
12.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-40986, NCT00004885
13.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N9841, ECOG-N9841, SWOG-N9841, NCT00005036, N9841
14.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000067967, FRE-FNCLCC-ACCORD-2, FFCD-9802, EU-20014, NCT00005979
15.

Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: CLB-9864, E-C9864, NCT00006103, C9864
16.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MRC-CR08-FOCUS, EU-20038, ISRCTN79877428, NCT00008060
17.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENENTECH-AVF2107g, UCLA-0008022, NCT00012233
18.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SANOFI-EFC4585, NCT00012389
19.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-001003701, SUGEN-SU5416.035, NCI-G01-1980, NCT00021281
20.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ACRIN-6655, NCT00023868
21.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP 4174B-307, CDR0000069014, PFIZER-A5961053, RP-64174-V-307, EORTC-40993, PETACC-3, PFIZER-XRP-4174B-307, NCT00026273
22.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-40015, NCT00064181
23.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000350016, U10CA031946, CALGB-80203, NCT00077233
24.

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA225-006, NCT00063141
25.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCI-2009-00639, N0147, U10CA025224, CDR0000355132, NCCTG-N0147, ECOG-N0147, NCT00079274
1     
New Search